RESTORATION OF AXONAL TRAFFICKING OF MITOCHONDRIA AVERTS COGNITIVE DECLINE IN MOUSE MODELS OF FAMILIAL ALZHEIMER'S DISEASE

eugenia trushina,liang zhang,song zhang,s trushin,izumi maezawa,leeway jin,duy h hua

DOI: https://doi.org/10.1016/j.jalz.2014.04.351

2014-01-01

Alzheimer s & Dementia

Abstract:Alzheimer's Disease (AD) is a devastating neurodegenerative disorder without cure. Lack of the understanding of early molecular mechanisms hinders the development of efficient therapeutics. We have previously demonstrated that alterations in mitochondrial dynamics precede the onset of memory phenotype and the development of amyloid plaques in three transgenic animal models of familial Alzheimer's Disease (FAD). Here we provide evidence that treatment with CP2, a member of a family of tricyclic pyrone compounds, restores axonal trafficking in vivo, and averts cognitive and motor deficit in FAD (APP, PS1 and APP/PS1) mice. Changes in mitochondrial dynamics and function in vivo and in vitro were evaluated using real-time imaging of mitochondrial motility; mitochondrial respiration and the rate of glycolysis were detected using a XF24 Seahorse Extracellular Flux Analyzer; evaluation of the activity of OXFOS Complexes I-V was done using enzymatic reactions; and metabolic changes associated with CP2 treatment were done using LC- and GC-MS-based metabolomics. Behavior and memory functions in treated and untreated animals were detected with a battery of well established tests including novel object recognition test, rotarod, hanging bar, Y-maze test, and activity in a cage. CP2 did not cause adverse side effects and did not affect animal breeding. CP2-treated animals maintained normal weight; they also outperform untreated FAD mice and age-and gender-matched non-transgenic littermates in a battery of tests. Cognitive protection was achieved within 2 months after treatment of presymptomatic animals. Investigation of the molecular mechanism revealed that CP2 treatment restores mitochondrial dynamics in neurons in vivo and in vitro. Alleviation of the motor and memory phenotype was accompanied by only partial reduction in amyloid burden. Moreover, we detected an increase in synaptophysin levels in the brain of CP2-treated APP/PS1 mice compared to untreated animals, which correlated with an improvement in cognitive function. Our findings, for the first time, demonstrated that restoration of mitochondrial trafficking protects against cognitive dysfunction in AD. Our data poise CP2 as a promising therapeutic compound validating mitochondrial motility as an early therapeutic target for AD.